TCM
VOR icon

Tang Capital Management’s Vor Biopharma VOR Stock Holding History

Tang Capital Management’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,000
Closed -$2.44M – 185
2025
Q3 		$2.44M Buy
+50,000
New +$2.01M 0.09% 118

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Tang Capital Management's VOR Position: Q4 2025 in Review

Tang Capital Management sold out of Vor Biopharma (VOR) in Q4 2025, closing a stake of 50,000 shares — an estimated $2.44M sold.

Tang Capital Management first reported a position in VOR in Q3 2025 and held it in 1 quarter. The position peaked at $2.44M in Q3 2025. 55 funds tracked by Wall St. Rank hold VOR as of Q4 2025.

  • Tang Capital Management reported no remaining Vor Biopharma position as of Q4 2025 after selling out during the quarter.
  • Tang Capital Management sold 50,000 Vor Biopharma shares in Q4 2025, an estimated $2.44M.
  • Tang Capital Management first reported a position in Vor Biopharma in Q3 2025 and held it in 1 quarter.
  • Tang Capital Management's Vor Biopharma position peaked at $2.44M in Q3 2025.
  • 55 funds tracked by Wall St. Rank held Vor Biopharma as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.